p53,化疗,胰腺癌
JournalofSurgicalOncology2003;82:111–120
p53AlterationIsNotanIndependentPrognosticIndicator,ButAffectstheEf cacyofAdjuvantChemotherapyinHumanPancreaticCancer
MINGDONG,MD,PhD,1YOSHINORINIO,MD,PhD,1*KUNIHIROYAMASAWA,MD,1TOMOKOTOGA,BEdu,1LISHUANGYUE,MD,2ANDTAKAYUKIHARADA,MD,PhD2
1
FirstDepartmentofSurgery,ShimaneMedicalUniversity,Izumo,Japan2
SecondDepartmentofPathology,ShimaneMedicalUniversity,Izumo,Japan
BackgroundandObjectives:Mutationsinthep53genearefoundinmorethan50%ofhumancancersandareobservedin60–80%ofpancreaticcancers.Theclinico-pathologicimplicationsofp53abnormalitiesandtheireffectsontheef cacyoftheadjuvantchemotherapyforpancreaticcancerremaincontroversial.
Methods:Weinvestigatedthep53statusincoreexon-4to-9(codon33–331)bydirectDNAsequencinginaseriesof72pancreaticcancersandanalyzedtheeffectsofp53abnormalitiesonthepatients’survivalandtheef cacyofadjuvantchemotherapy.Results:p53mutationswerefoundin62.5%(45/72)ofcases,including38pointmutationsand7frameshiftmutations.Thesubtypesofp53mutationsincluded68.9%(31/45)transitionsand15.6%(7/45)transversions.39.5%(15/38)ofpointmutationswere(Arg)to(His)mutationatcodon-273ofexon-8.34.2%(13/38)ofpointmutationswere(Arg)to(Trp)mutationatcodon-248ofexon-7.Ofsevenframeshiftmutations,fourwereseenatexon-4,twoatexon-5,andoneatexon-6.Ofoverallcases,p53abnormalitieswerenotassociatedwithapoorlydif-ferentiatedgradeandanadvancedstage.Therelationshipofadjuvantchemotherapytosurvivalisapproachingstatisticalsigni cance.Univariateanalysisshowedthatinthep53mutationgroup,thepatientswhoreceivedadjuvantchemotherapyhadabettersurvivalratiothanthatofpatientswhodidnotdo.Multivariateanalysisindicatedthatinthegroupwithp53mutations,thesigni cantfactorsforsurvivalwereadju-vantchemotherapy,histologicgrade,andclinicalstage.However,inthegroupwithawild-typep53gene,onlyhistologicgradewasasigni cantfactor.Inaddition,34.7%(25/72)ofthecasesharborp53polymorphismmutationonlyatcodon-72ofexon-4,whichdidnotshowanysigni canteffectonthepathology,prognosis,andef cacyofadjuvantchemotherapyofthepancreaticcancers.
Conclusions:Ap53abnormalitywasnotanindependentfactorforevaluatingtheprognosisofpatientswithpancreaticcancer,butwasabene cialindicatorforselect-ingareasonablestrategyofadjuvantchemotherapyagainstpancreaticcancer.
J.Surg.Oncol.2003;82:111–120.
ß2003Wiley-Liss,Inc.
KEYWORDS:p53;pointmutation;polymorphism;pancreaticcancer;
chemotherapy
MingDongandLishuangYuearecurrentlyattheDepartmentofMedicine,StateUniversityofNewYork,StonyBrook,NY.
*Correspondenceto:YoshinoriNio,MD,FirstDepartmentofSurgery,ShimaneMedicalUniversity89-1,Enya-cho,Izumo,Shimane693-8501,Japan.Fax:81-853-20-2222.
E-mail:fsurgery@shimane-med.ac.jpAccepted17September2002DOI10.1002/jso.10186
PublishedonlineinWileyInterScience(doc.guandang.net).
Theincidenceofpancreaticcancerhasrisenmarkedlyduringthelasthalf-century.Now,pancreaticcanceristhefourthor fthleadingcauseofcancerdeathinthedeve-lopedWesterncountries[1]andJapan[2]andremainsthemostlethalofthecommonmalignancies.Thelackofanatomicbarrierstoprotectagainstlocalin ltrationandthebiologicpropensitytoinvadethelymphatics,nerves,
ß2003Wiley-Liss,Inc.
Efficacy of percutaneous ethanol injection in the adjuvant treatment of hepatocellular carcinoma 隐藏>> Efayo ect oseh l etnih fic fruaeu tao jci tecpnnino...
p53 alteration affects t... 暂无评价 10页 免费 Adjuvant chemotherapy of....The Cochrane Collaboration and published in The Cochrane Library 2012, Issue ...
Efficacy of percutaneous ethanol injection in the adjuvant treatment of hepatocellular carcinoma 隐藏>> Efayo ect oseh l etnih fic fruaeu tao jci tecpnnino...
热门文档